BOSTON, Jan. 28, 2022 /PRNewswire/ -- Environmental
Impact Acquisition Corporation ("ENVI" or the "Company")
(Nasdaq: ENVI) today announced that it had achieved a quorum for
the special meeting of its shareholders to be held on February 1, 2022 (the "Special Meeting"), in
connection with its business combination with GreenLight
Biosciences Inc. ("GreenLight"), a biotechnology company dedicated
to making ribonucleic acid (RNA) products affordable and accessible
for human health and agriculture.
ENVI's shareholders who have submitted proxies to date on the
proposals included in the Company's proxy statement/prospectus for
the Special Meeting have overwhelmingly voted in support of the
business combination and all other proposals to be voted on at the
meeting. Accordingly, it is anticipated that the business
combination and the other proposals will be approved at the Special
Meeting. However, shareholders may change or revoke their proxies
before or at the Special Meeting.
The business combination, if approved by ENVI shareholders, is
expected to close on February 2, 2022. Upon the closing of the
business combination, common stock and warrants of the combined
company are expected to begin trading on February 3,
2022, on Nasdaq under the ticker symbol GRNA.
Environmental Impact Acquisition Corp. Stockholder
Vote
Stockholders who own shares of Environmental Impact Acquisition
Corp., as of the Record Date should submit their vote promptly and
no later than 11:59 p.m. Eastern Time
on January 31, 2022. Environmental
Impact Acquisition Corp. stockholders who need assistance in
completing the proxy card, need additional copies of the proxy
materials, or have questions regarding the Special Meeting may
contact Environmental Impact Acquisition Corp.'s proxy solicitor,
D.F. King & Co., Inc., by telephone toll-free at (866) 620-2535
or collect at (212) 269-5550 or by email at ENVI@dfking.com
About GreenLight
Founded in 2008, GreenLight aims to address some of the world's
biggest problems by delivering on the full potential of RNA for
human health and agriculture. In human health, this includes mRNA
vaccines and therapeutics. In agriculture, this includes RNA to
protect honeybees and a range of crops. The company's breakthrough
cell-free RNA manufacturing platform, which is protected by
numerous patents, allows for cost-effective production of RNA.
GreenLight's human health product candidates are in the
pre-clinical stage, and its product candidates for the agriculture
market are in the early stages of development or regulatory review.
For more information, visit
https://www.greenlightbiosciences.com/
In August 2021, GreenLight
Biosciences announced plans to become publicly listed through a
business combination with Environmental Impact Acquisition Corp.
(Nasdaq: ENVI).
For more information, visit greenlightbiosciences.com
About Environmental Impact Acquisition Corporation
Environmental Impact Acquisition Corp. is a Special Purpose
Acquisition Company. The Company is sponsored by CG Investments
Inc. VI, an affiliate of Canaccord Genuity, which manages several
investment vehicles.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws with respect to the
business of GreenLight Biosciences, Inc. and its proposed
transaction with Environmental Impact Acquisition Corp. ("ENVI"),
including statements regarding the anticipated benefits and uses of
GreenLight's product candidates, the market opportunities for
GreenLight's product candidates, timing of clinical trials, and the
timing of commercial launch of product candidates, and the
anticipated business combination with ENVI. These forward-looking
statements are generally identified by the words "believe,"
"project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result"
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from these
forward-looking statements, including but not limited to: the need
to obtain regulatory approval for GreenLight's product candidates;
the risk that clinical trials will not demonstrate that
GreenLight's therapeutic product candidates are safe and effective;
the risk that GreenLight's product candidates will have adverse
side effects or other unintended consequences, which could impair
their marketability; the risk that GreenLight's product candidates
do not satisfy other legal and regulatory requirements for
marketability in one or more jurisdictions; the risks of enhanced
regulatory scrutiny of mRNA solutions; the risk of significant
delays in research, development, testing, clinical trials and
regulatory approval; the potential inability to achieve
GreenLight's goals regarding scalability and affordability of its
product candidates; the anticipated need for additional capital to
achieve GreenLight's business goals; changes in the industries in
which GreenLight operates; changes in laws and regulations
affecting the business of GreenLight; the risk that the proposed
business combination with ENVI may not be completed in a timely
manner or at all, which may adversely affect the price of ENVI's
securities; the failure to satisfy conditions to the consummation
of the transaction; the occurrence of any event, change or other
circumstance that could give rise to the termination of the
business combination agreement; risks that the proposed transaction
disrupts current plans and operations of GreenLight; and the
potential inability to implement or achieve business plans,
forecasts, and other expectations after the completion of the
proposed transaction. The foregoing list of factors is not
exhaustive. Readers should carefully consider the foregoing factors
and the other risks and uncertainties described in the "Risk
Factors" section of the registration statement on Form S-4
discussed below and other documents filed by ENVI from time to time
with the SEC. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and ENVI and GreenLight assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise. Neither ENVI nor GreenLight gives any
assurance that GreenLight or ENVI, or the combined company, will
achieve any result described in any forward-looking statement.
Important Information and Where to Find It
ENVI has filed a registration statement on Form S-4 with the
SEC, which includes a document that serves as a preliminary proxy
statement/prospectus of ENVI, referred to as a proxy
statement/prospectus. The registration statement was declared
effective by the SEC on January 13,
2022 and the definitive proxy statement/prospectus and other
relevant documents have been filed with the SEC and mailed to
ENVI's stockholders as of the Record Date.
This press release does not contain all of the information
contained in the final proxy statement/prospectus or other
documents filed with the SEC. Before making any voting decision,
investors and security holders of ENVI are urged to read the
registration statement, the final proxy statement/ prospectus and
all other relevant documents filed or that will be filed with the
SEC in connection with the proposed transaction as they become
available because they will contain important information about the
proposed transaction. Investors and security holders will be able
to obtain free copies of the registration statement, the final
proxy statement/prospectus and all other relevant documents filed
with the SEC by ENVI through the website maintained by the SEC at
www.sec.gov or by sending a written request to ENVI at:
ENVI.Inquiries@cgf.com.
No Offer or Solicitation
This press release shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed business combination. This press release
shall also not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall there be any sale of
securities in any states or jurisdictions in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of the Securities Act of 1933,
as amended.
Participants in the Solicitation
ENVI, GreenLight and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from ENVI's shareholders in connection with the proposed
transaction. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
business combination are contained in the final proxy
statement/prospectus. You may obtain free copies of these documents
as described above.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/envi-announces-quorum-to-pass-business-combination-with-greenlight-biosciences-and-achievement-of-all-transaction-requirements-following-the-redemption-deadline-301470602.html
SOURCE GreenLight Biosciences, Inc.